Half Year 2025 Redcare Pharmacy NV Earnings Call Transcript
Key Points
- Redcare Pharmacy NV (SAEYY) reported a 27% year-over-year increase in group sales, showcasing strong organic growth in both non-Rx and Rx segments.
- The company achieved a significant 155% year-over-year growth in Rx sales in Germany, indicating strong market share gains.
- Adjusted EBITDA margin improved from 1.3% in Q1 to 2.6% in Q2, demonstrating operational efficiency and cost management.
- The company successfully launched a EUR300 million convertible bond and bought back 70% of the existing bond, strengthening its balance sheet.
- Redcare Pharmacy NV (SAEYY) added 0.4 million active customers, reaching a total of 13.5 million, and maintained a stable Net Promoter Score (NPS) of 64.
- Despite the growth, the adjusted EBITDA margin remains relatively low at 2.6%, indicating room for improvement towards the long-term target of 8%.
- The company faces challenges in maintaining consistent customer growth, with a slower increase in active customers compared to previous quarters.
- There is uncertainty regarding the impact of upcoming regulatory changes, such as the German Supreme Court's ruling on Rx bonuses and advertising.
- The company anticipates elevated investment levels due to ongoing projects like the distribution center in Austria and e-Rx automation, which may impact short-term cash flow.
- Redcare Pharmacy NV (SAEYY) must navigate competitive dynamics in the DACH region, particularly in the non-Rx segment, to sustain its growth trajectory.
Ladies and gentlemen, welcome to the half-year Q2 2025 earnings with analysts and investors conference call. I'm Sergeon, the Chorus Call operator. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand you over to Olaf Heinrich, CEO. Please go ahead.
Thank you very much and good morning to everybody and a very warm welcome from our side. Let's have a look into today's agenda. So first of all, we would like to talk about financial performance, then an update on our regulatory landscape, then I update on our Rx development. And then by the end, an outlook and guidance for the remaining part of the year.
If we go to the next slide, we can start with the financial performance. Group sales are up 27% year-over-year, so we are showing a continued strong growth that's fully organic and it's in both areas, non-Rx and Rx.
In non-Rx, we are showing a growth of 18%. 60% in the DACH region
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
